Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 12Brain Neoplasms 6Breast Neoplasms, Male 5Glioblastoma 4Gliosarcoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oligodendroglioma 2Glioma 2Gallbladder Neoplasms 2Ependymoma 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Astrocytoma 2Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms 1Melanoma 1Medulloblastoma 1Insulin-Like Growth Factor I, Resistance To 1Familial ependymoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × Lapatinib × Clear all
NCT01264081 2019-11-13

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
34 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡